The usefulness of QuantiFERON CMV in an intermediated risk of CMV infection in kidney transplant recipient

Not Applicable

Recruiting

• Conditions: Intermediated risk for CMV DNAemia after kidney transplant; QuantiFERON CMV, CMV DNAemia, Kidney transplantation

• Registration Number: TCTR20200901006
• Lead Sponsor: Ratchadaphiseksomphot Endowment Fund

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-09-01
• Study Completion: 2021-12-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

1.Age ≥ 18 year olds
2.Living or deceased donor kidney transplantation without preformed DSA
3.Low to intermediate risk for CMV infection after kidney transplantation

Exclusion Criteria

1. White blood count < 1,500/mm3
2. Delay graft function with dialysis dependence)
3. Severe infection
4. Advanced malignancy
5. Pregnancy
6. Reject consent

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ROC curve of QuantiFERON CMV on Incidence of CMV DNAemia at day 1 month after kidney transplantation and end of the study QuantiFERON CMV, CMV viral load

Secondary Outcome Measures

Name	Time	Method
Sensitivity, specificity and accuracy of QuantiFERON CMV on incidence of CMV detection at day 1 month after kidney transplantation and end of the study QuantiFERON CMV, CMV viral load